Kintor Pharmaceutical Completes Patient Enrollment for Phase III Trial of KX-826 Tincture for Male AGA Treatment in China

Reuters
Jul 31
<a href="https://laohu8.com/S/KNTPF">Kintor Pharmaceutical</a> Completes Patient Enrollment for Phase III Trial of KX-826 Tincture for Male AGA Treatment in China

Kintor Pharmaceutical Ltd. has announced the completion of patient enrollment in the Phase III stage of a pivotal clinical trial for KX-826 tincture 1.0%, aimed at treating male adult androgenetic alopecia (AGA) in China. The trial enrolled 666 patients and is characterized by a multi-center, randomized, double-blind, vehicle-controlled design. This Phase III stage involves a 24-week treatment period, followed by a 2-week safety observation period, across 25 clinical research centers in China. The Phase II stage of the trial previously met its primary endpoints, showing statistically significant and clinically meaningful outcomes in terms of efficacy and safety. The completion of the Phase III stage is anticipated by early 2026. Results from this stage have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kintor Pharmaceutical Ltd. published the original content used to generate this news brief on July 31, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10